Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer

调节 HSP70/STUB1 机制治疗耐药性前列腺癌

基本信息

  • 批准号:
    10678891
  • 负责人:
  • 金额:
    $ 35.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT ABSTRACT Prostate cancer will claim lives of over 30,000 American men in 2020 alone. The disease evolves from primary tumors to castrate-resistant prostate cancer (CRPC), which only takes around 2-3 years. CRPC is still driven by androgens such as testosterone which is why anti-androgen drugs are widely used to treat the disease. These drugs include enzalutamide (XTANDI®), abiraterone acetate (ZYTIGA®) and apalutamide (ERLEADA™). Although these drugs are highly effective initially, patients often quickly develop resistant disease to these drugs. Therefore, there is an urgent need to find strategies that control the emergence of anti- androgen resistant prostate cancer. Researchers have shown that drug resistant CRPC often occurs due to expression of a variant form of receptor called androgen receptor variant-7 (AR-V7). This receptor can be activated independent of androgen. Data from my group shows that protein degrading enzyme (STUB1) and its chaperone protein (HSP70) are altered in resistant CRPC cells. This HSP70/STUB1 complex is a critical regulator of protein stability/half-life. We found that HSP70/STUB1 is responsible for AR/AR-V7 proteins homeostasis (proteostasis) and remaining active for long periods. We have shown that modulating the HSP70/STUB1 complex with a Food and Drug Administration (FDA) approved drug used for parasite infection namely, niclosamide, reduces the levels of AR-V7 and importantly resensitizes resistant prostate cancer to anti-androgen therapy. However, niclosamide has a poor characteristic that is hard to reach satisfied concentration in blood as a cancer therapeutic. To address this, we modified niclosamide to yield a range of potent HSP70/STUB1 modulators (HSMs) and one of the small molecule compounds known as HSM-7, which has a better bio-distribution profile and superior effects on killing drug resistant prostate tumors. The overarching goal of this application is to develop HSMs and build a strong rationale for translating the drug to the clinic to treat patients with lethal CRPC disease. In this project, we will study HSM-7 on its regulation of HSP70/STUB1/AR-V7 ternary complex which will be critical to strategize to overcome anti-androgen resistance. We will discover the multiplicity targets regulated by HSMs through HSP70/STUB1 machinery and dissect how ubiquitination alteration by HSMs treatment controls oncogenic protein turnover. Additionally, we will evaluate the drug properties of HSM-7 and test its efficacy in novel patient tumor derived animal and cell models of CRPC for future clinical trial initiation. The outcomes of the proposed studies will provide a strong rationale for translating HSM-7 into the clinical setting and in addressing the major unmet need of overcoming next generation anti-androgen resistance in CRPC patients. We believe that HSM-7 will ultimately increase the overall survival and improve the quality of life men diagnosed with CRPC.
项目摘要 仅在2020年,前列腺癌就将夺去3万多名美国男性的生命。这种疾病从原发性 从肿瘤到去势抵抗性前列腺癌(CRPC),只需2-3年。CRPC仍在推动 这就是为什么抗雄激素药物被广泛用于治疗这种疾病。 这些药物包括恩杂鲁胺(XTANDI®)、醋酸阿比特龙(ZYTIGA®)和阿帕鲁胺(apalutamide)。 (ERLEADA™)。虽然这些药物最初非常有效,但患者通常很快产生耐药性 这些疾病的药物。因此,迫切需要找到控制反政府武装出现的战略, 雄激素抵抗性前列腺癌研究人员已经表明,耐药CRPC经常发生, 雄激素受体变体-7(AR-V7)。该受体可以是 不依赖于雄激素激活。来自我的小组的数据表明,蛋白质降解酶(STUB 1)及其 伴侣蛋白(HSP 70)在耐药CRPC细胞中发生改变。这种HSP 70/STUB 1复合物是一种关键的 蛋白质稳定性/半衰期的调节剂。我们发现HSP 70/STUB 1与AR/AR-V7蛋白有关 体内平衡(蛋白质平衡)和长期保持活性。我们已经证明, HSP 70/STUB 1复合物与食品和药物管理局(FDA)批准的用于寄生虫感染的药物 即氯硝柳胺,降低AR-V7的水平,重要的是使耐药前列腺癌对 抗雄激素治疗然而,氯硝柳胺具有较差的特性,难以达到满意 血液中的浓度作为癌症治疗剂。为了解决这个问题,我们修改了氯硝柳胺, 有效的HSP 70/STUB 1调节剂(HSM)和一种称为HSM-7的小分子化合物, 具有更好的生物分布特征和对抗药性前列腺肿瘤的上级杀伤作用。的 本申请的首要目标是开发HSM,并为将药物转化为 临床治疗致命性CRPC疾病的患者。在本项目中,我们将研究HSM-7对细胞凋亡的调控作用。 HSP 70/STUB 1/AR-V7三元复合物,这对于制定克服抗雄激素抗性的策略至关重要。 我们将通过HSP 70/STUB 1机制发现HSMs调控的多重靶点,并分析其如何调控HSP 70/STUB 1的表达。 HSMs处理引起的泛素化改变控制致癌蛋白质周转。此外,我们将评估 本文描述了HSM-7的药物性质,并测试了其在新的患者肿瘤衍生的动物和细胞模型中的功效。 CRPC用于未来临床试验启动。拟议研究的结果将为以下方面提供强有力的依据: 将HSM-7转化为临床环境,并解决克服下一个 CRPC患者产生抗雄激素抵抗。我们相信,HSM-7将最终提高 总生存期和改善生活质量的男性诊断为CRPC。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chengfei Liu其他文献

Chengfei Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chengfei Liu', 18)}}的其他基金

Targeting intracrine steroidogenesis in anti-androgen resistant prostate cancer
靶向抗雄激素抵抗性前列腺癌的分泌内类固醇生成
  • 批准号:
    10742116
  • 财政年份:
    2023
  • 资助金额:
    $ 35.52万
  • 项目类别:
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer
剖析蛋白质稳态在抗雄激素抵抗性前列腺癌中的作用
  • 批准号:
    10211202
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer
剖析蛋白质稳态在抗雄激素抵抗性前列腺癌中的作用
  • 批准号:
    10675431
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer
调节 HSP70/STUB1 机制治疗耐药性前列腺癌
  • 批准号:
    10298903
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer
剖析蛋白质稳态在抗雄激素抵抗性前列腺癌中的作用
  • 批准号:
    10353422
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer
调节 HSP70/STUB1 机制治疗耐药性前列腺癌
  • 批准号:
    10442601
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:

相似海外基金

African American (AA) Communities Speak: Partnering with AAs in the North and South to Train Palliative Care Clinicians to Address Interpersonal and Systemic Racism and Provide Culturally Aligned Care
非裔美国人 (AA) 社区发言:与北部和南部的 AA 合作,培训姑息治疗临床医生,以解决人际和系统性种族主义并提供文化一致的护理
  • 批准号:
    10734272
  • 财政年份:
    2023
  • 资助金额:
    $ 35.52万
  • 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
  • 批准号:
    10541028
  • 财政年份:
    2022
  • 资助金额:
    $ 35.52万
  • 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
  • 批准号:
    10684239
  • 财政年份:
    2022
  • 资助金额:
    $ 35.52万
  • 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
  • 批准号:
    10395616
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
  • 批准号:
    10786490
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
  • 批准号:
    10821849
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
  • 批准号:
    10384110
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
  • 批准号:
    10336591
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
Community-Academic Partnerships to Address COVID-19 Inequities within African American Communities
社区学术伙伴关系解决非裔美国人社区内的 COVID-19 不平等问题
  • 批准号:
    10245326
  • 财政年份:
    2021
  • 资助金额:
    $ 35.52万
  • 项目类别:
Engaging scientists and communities to address the impacts of substance abuse on American Indian and Alaska Native children and families: The Native Children's Research Exchange Annual Meetings
让科学家和社区参与解决药物滥用对美洲印第安人和阿拉斯加原住民儿童和家庭的影响:原住民儿童研究交流年会
  • 批准号:
    10657317
  • 财政年份:
    2020
  • 资助金额:
    $ 35.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了